Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2138835 | Leukemia Research | 2008 | 4 Pages |
Abstract
Adjuvant chemotherapy and radiation therapy for breast cancer are associated with therapy-related acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS), but little is known about additional risk factors. Thirty-four patients with AML (n = 26)/MDS (n = 8) following breast cancer (cases) were compared with 2029 breast cancer patients without AML/MDS (controls). Cases were older at breast cancer diagnosis (mean 60.2 years versus 54.5 years; p = 0.01) and more commonly had additional cancers (29% versus 4.9%; p < 0.0001) and ≥4 first-degree relatives with any type of cancer (OR: 5.37, CI: 1.44–19.9). Thus risk factors for AML/MDS following breast cancer include older age, other cancers and multiple first-degree relatives with cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Aruna Padmanabhan, Julie A. Baker, Gary Zirpoli, Sheila N.J. Sait, Laurie A. Ford, Kirsten B. Moysich, Maria R. Baer,